6.3 Packaging, Composites, and Comprehensive APCs

Packaging, Composites, and Comprehensive APCs

Quick Answer: Under OPPS, packaged items are integral to a primary service, so CMS does not make a separate APC payment for them. CY 2026 packaging thresholds in CMS's MLN Medicare Payment Systems booklet are $140 per day for drugs, biologicals, and therapeutic radiopharmaceuticals, and $655 per day for diagnostic radiopharmaceuticals. Comprehensive APCs (C-APCs) go further: a J1 primary procedure (or a qualifying J2 observation encounter) packages most adjunctive services on the claim, not just on the line.

Why packaging questions feel like coding questions

AAPC's COC payment items often look like CPT items. The record shows an ED visit, a chest X-ray, a low-cost antiemetic, and eight hours of observation. The coding is not complete until you know which of those lines can generate its own APC. Packaging is claim-context logic. The same Q1 radiology code is payable on Tuesday's standalone test and packaged on Wednesday's ED visit.

CMS's MLN booklet cites 42 CFR 419.2(b) for types of packaged items and 42 CFR 419.2(c) for costs OPPS does not include. Hospitals still report the HCPCS and the charge. Future APC weights depend on those packaged costs.

Unconditional packaging versus conditional packaging

Unconditional packaging is status indicator N. Payment is always packaged into other OPPS services on the claim, including outliers. Supplies, many add-on codes, and observation hourly code G0378 sit here. G0378 has been SI N since 2008: no separate observation APC for the hourly code itself.

Conditional packaging uses the Q family. Medicare Claims Processing Manual, Chapter 4, §10.4:

1. Q1 (STV-packaged): separate payment only if the claim has no service with SI S, T, or V. If an S, T, or V is present, the Q1 packages into that major service. If several Q1 codes appear with no S/T/V, CMS pays the Q1 assigned to the highest-paid APC and packages the rest.
2. Q2 (T-packaged): separate payment only if the claim has no SI T. A T procedure swallows the Q2. Multiple Q2 codes with no T pay the highest Q2 APC and package the others.
3. Q3 (composite candidate): when HCPCS that meet composite criteria appear on the same date of service, CMS makes one payment for the set rather than paying each code. Cardiac resynchronization therapy pairing CPT 33249 and 33225 on the same date is the manual's long-standing example. If the codes fall on different dates, standard APC logic applies.
4. Q4 (conditionally packaged laboratory): packaged if billed with J1, J2, S, T, V, Q1, Q2, or Q3. If the 13X claim has none of those payable OPPS services, the I/OCE changes the SI to A and the Clinical Laboratory Fee Schedule pays. Reference laboratory 14X claims pay Q4 as A. CMS discontinued modifier L1 for "unrelated lab" on January 1, 2017; do not resurrect L1 on a 2026 item.

Mixed Q1 and Q2 on a claim with no S/T/V: CMS pays the highest-paid Q1 or Q2 and packages the others. If a composite also qualifies, Q1/Q2 package into the composite.

Drug and radiopharmaceutical thresholds

CMS's MLN booklet (and the CY 2026 OPPS final) set:

Policy-packaged products package regardless of cost under 42 CFR 419.2(b) — for example, drugs that function as supplies in a surgical procedure. Crossing $140 does not unpackage a policy-packaged product. Pass-through drugs (G) pay separately during the pass-through window even when a similar product would otherwise package.

For CY 2026, CMS generally pays most non-pass-through separately payable drugs at ASP + 6% (biosimilars: ASP + 6% or 8% of the reference product, per MM14361). ASP files update quarterly, so the January Pricer rate may differ from the rate printed in the November final rule.

Comprehensive APCs: J1 and J2

A J1 C-APC packages adjunctive items, services, and procedures into the most costly primary procedure at the claim level. Medicare Claims Processing Manual, Chapter 4, §10.2.3 lists services excluded from C-APC packaging:

• Ambulance services
• Brachytherapy sources (SI U)
• Diagnostic and screening mammography
• Physical therapy, speech-language pathology, and occupational therapy reported on a separate facility claim for recurring services
• Pass-through drugs, biologicals, and devices (SI G or H)
• Preventive services defined in 42 CFR 410.2
• Self-administered drugs that do not function as supplies in the comprehensive service
• SI F services (certain CRNA services, hepatitis B vaccines, corneal tissue acquisition)
• SI L vaccines (influenza, pneumococcal, COVID-19)
• Certain Part B inpatient ancillary services in specified benefit-exhaustion situations
• Services assigned to a New Technology APC
• Unclassified drug/biological C9399

If the exclusion is not on that CMS list, assume the adjunctive service packages into the J1. New Technology APC exclusion exists so CMS can collect claims data on new services instead of burying them inside a C-APC.

J2 is not "observation always packages." J2 means the service may pay through a C-APC when a specific combination is present. Beginning January 1, 2016, CMS pays comprehensive APC 8011 (Comprehensive Observation Services) when all of the following are met (Claims Processing Manual, Chapter 4, §290.5.3):

• G0378 units equal or exceed 8 hours
• The claim also has a Type A or B ED visit, hospital clinic visit G0463, critical care 99291, or direct referral G0379 (with G0379 date-of-service rules in the manual)
• No procedure with SI T or J1 is on the claim
• Observation is billed on Type of Bill 13X
• Physician evaluation and timed observation documentation are in the record

There is no diagnosis limitation for APC 8011. If observation is reported with a T surgical procedure, or hours are under 8, comprehensive observation payment is not made and usual APC logic applies. G0378 remains packaged (N) either way. Direct referral G0379 can pay under APC 5013 or package into 8011 when its own criteria are met.

CY 2026 unpackaging: skin substitutes

From CY 2014 through 2025, CMS unconditionally packaged skin substitute products into application procedures and split application into high-cost and low-cost groups. For CY 2026, CMS-1834-FC and MM14361 unpackage the product from application CPT 15271–15278 and create:

• APC 6000 — PMA skin substitute products
• APC 6001 — 510(k) skin substitute products
• APC 6002 — 361 HCT/P skin substitute products

CMS groups those APCs by FDA regulatory status, not by the old high/low price bands. For CY 2026 CMS uses a single rate of $127.14 per cm² for APCs 6000–6002. Product codes use new SI S1. CMS deleted low-cost application HCPCS C5271–C5278 effective December 31, 2025. Application CPT 15271–15278 remain. CMS continues to package add-on application codes 15272, 15274, 15276, and 15278 in the HOPD. Unlisted product codes Q4431 (PMA), Q4432 (510(k)), and Q4433 (361 HCT/P) exist so a newly authorized product can pay before it has a specific HCPCS.

Non-opioid pain treatments, 2025–2027

Section 4135 of the Consolidated Appropriations Act, 2023 created temporary additional payments for qualifying non-opioid treatments for pain relief. CMS-1834-FC continues separate payment in the HOPD and ASC from January 1, 2025 through December 31, 2027. For CY 2026 CMS finalized five drugs and 11 devices that meet the statutory definition and pay separately in both settings. Statute caps the separate payment at an estimated average of 18% of the OPD fee schedule amount for the service furnished with the product. MM14361 points to Tables 21–22 for the product list and payment limitation and notes Pricer caps for status indicators K1 and H1 used with that policy. Do not package a qualifying Section 4135 product just because it looks like a surgical supply.

Candidate scenario: observation that does — and does not — become 8011

Marcus codes two Medicare outpatients overnight in the same unit.

Encounter A: ED visit 99284, G0378 × 10 hours, chest X-ray (Q1), and a $90 antiemetic (below the $140 threshold, SI N). No T or J1 procedure. The I/OCE can pay C-APC 8011 for the extended encounter. The X-ray and the antiemetic package. Marcus still reports every code.

Encounter B: Same ED visit and 10 hours of observation, plus a same-claim SI T laparoscopic procedure. Comprehensive observation does not apply. Usual APC logic pays the T procedure (and the V visit may package or pay depending on the rest of the claim logic), and G0378 remains N. Marcus does not "convert" the T procedure to a clinic visit to chase APC 8011. Site of service and the procedure performed control the claim.

If Encounter A also included a sheet-form skin substitute product, CY 2026 logic would look for SI S1 and APCs 6000–6002 at $127.14/cm², not the retired high/low application packaging. Application add-on CPT 15272 still packages in the HOPD.

CMS pages to recheck when thresholds move

• MLN Medicare Payment Systems (CY 2026 $140 / $655)
• Medicare Claims Processing Manual, Chapter 4, §§10.2.1, 10.2.3, 10.4, 290.5.3
• CMS-1834-FC fact sheet (skin substitutes; non-opioid 2025–2027)